Showcasing tailored lactose for DPI at Global Pulmonary Health 2025

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will be a leading presence as principal sponsor of the upcoming Global Pulmonary Health: Inhalation & Respiratory 2025 Conference in Munich.

MEGGLE will also contribute to the conference scientific program, with its Business Development Manager for Inhalation Excipients, Tristan Mul, leading off the Day 1 Session 4 focusing on Advanced Pulmonary Therapies (May 22, 1330-1410 hrs.).

Tailored lactose for DPI formulations

Tristan Mul’s address on ‘Optimization of Generic DPI Formulations: The role of Lactose Grades within Blending’ is to enhance the effectiveness of Dry Powder Inhaler (DPI) formulations by exploring how different grades of lactose impact the blending process.

Mr. Mul’s role at MEGGLE specializes in inhalation-focused excipients, principally the InhaLac^® range of sieved, milled, and micronized lactose for Dry Powder Inhaler (DPI) and other applications, offering technical support to global clients in nasal and inhalation sectors. He has almost 20 years’ experience in the field of DPI formulations, with previous posts at TEVA (Netherlands), Chiesi Farmaceutici (Italy), and Sandoz Aeropharm in Germany.

About MEGGLE

Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose^®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose^® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac^®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About Global Pulmonary Health 2025

The annual Global Pulmonary Health: Inhalation & Respiratory Conference provides a forum for leading experts, researchers, and healthcare professionals to discuss latest development, emerging trends and leading-edge solutions in pulmonary health and respiratory care.

The 2025 Global Pulmonary Health Conference is a two-day event, opening May 22 at the Grand Hotel Palladium in Munich.

The conference will feature more than 20 expert speakers from industry and academia, exploring a wide range of topics, including Advances in Pulmonary Disease Research, Innovative Therapies for Chronic Obstructive Pulmonary Disease (COPD), Role of Genetics in Asthma and Allergy Management, Emerging Trends in Lung Cancer Treatment, Pediatric Pulmonology, and Telemedicine in Pulmonary Care. It will also include workshops and panel discussions.

The event is organized by Prague-based VNA, with further information at:  https://vna-events.com/global-pulmonary-health-summit-2025/

Resources

Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information.